Prognostic significance of combined PD-L1 expression in malignant and infiltrating cells in hepatocellular carcinoma treated with atezolizumab and bevacizumabFRONTIERS IN IMMUNOLOGYIF5.92024-12-100OAAI
Dynamic Peripheral T-Cell Analysis Identifies On-Treatment Prognostic Biomarkers of Atezolizumab plus Bevacizumab in Hepatocellular CarcinomaLIVER CANCERIF9.12024-09-021OAAI
Differential liver function at cessation of atezolizumab-bevacizumab versus lenvatinib in HCC: a multicenter, propensity-score matched comparative studyFRONTIERS IN ONCOLOGYIF3.32024-02-280OAAI
EpCAM-high liver cancer stem cells resist natural killer cell-mediated cytotoxicity by upregulating CEACAM1JOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62020-03-2690OAAI
Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and liver-related events in patients with chronic hepatitis B: A propensity score analysisJOURNAL OF HEPATOLOGYIF332019-04-013PREAI
Helicobacter pylori infection is not associated with nonalcoholic fatty liver diseaseWORLD JOURNAL OF GASTROENTEROLOGYIF5.42016-01-0162OA
Outcome of transarterial chemoembolization-based multi-modal treatment in patients with unresectable hepatocellular carcinomaWORLD JOURNAL OF GASTROENTEROLOGYIF5.42015-01-0124OA
Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis肝癌合并门静脉癌栓的肝动脉灌注化疗WORLD JOURNAL OF GASTROENTEROLOGYIF5.42013-01-0134OA
Family history influences the early onset of hepatocellular carcinomaWORLD JOURNAL OF GASTROENTEROLOGYIF5.42012-06-0724PRE
Durability of viral response after off-treatment in HBeAg positive chronic hepatitis BWORLD JOURNAL OF GASTROENTEROLOGYIF5.42012-01-0133OA